Amryt Pharma Share Discussion Threads

[papillon] 21/2/2019 13:08

Bronxville
Posts: 794
Opinion:
No Opinion
Price:
15.55
RE: Big seller out there?
Today 12:27
Are there questions on liver toxicity for AP101?
Where did this come from?

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

LOL. LOL. LOL. LOL.

Are you really as stupid, Bronxville, as some of your posts imply? LOL. mdalos was talking about MTFB and then, somewhat fancifully, wondered whether the same liver toxicity fears could apply to AP101 without any evidence whatsoever. MTFB's antibiotic is taken internally and there have always been fears over it's liver toxity. AP101 is a cream applied to the skin. Liver toxicity has never, ever, been a worry for AP101.

You're either as thick as a two short planks conspiracy theorist, Bronxville, or you are trying to depress the AMYT share price Seeing I sold some of my shares earlier today and would like to buy them back again at a much cheaper price my message to you is keep on posting negatively on the lse asylum bb! LOL. LOL.

[papillon] 21/2/2019 12:52

Surely the MTFB bb is the best place to discuss MTFB mdalos?

Meanwhile back to the mundane business of AMYT. Sold some shares this morning. This could easily drop back to last November's low. Who knows? The share price needs good news, but news could be a few months away when the 2018 annual results RNS is released. I'll keep my remaining shares as my core holding and will top up again when I think the share price has bottomed out.

[bermudashorts] 20/2/2019 19:44

mdalos -

re. Motif Bio, there is no suggestion at all that the issue was with the trial design or any failure to monitor major organs. Indeed both trials were designed following advisory meetings with the FDA. The FDA issued a CRL because they have a concern regarding liver toxicity. Iclaprim is an antibiotic that is administered intravenously to hospitalised patients with serious infections. Their organs were monitored very closely!

MTFB have been so badly affected by what hopefully will be a delay in approval because they only have this one product in their pipeline and they have low cash reserves. Amryt already have a revenue generating product on the market and 3 others in their pipeline.

There are always risks with any clinical trial but I would have thought last on the list would be that patients aren't monitored closely enough. Trial protocols have to be approved by both the regulators and eithics committees and also worth remembering that the AP101 trial has had an interim review by an independent DMC who have viewed unblinded data.

[ih_701710] 20/2/2019 18:52

very quiet here. When should this pearl start?

[papillon] 18/2/2019 12:42

Who knows, mdalos? AP101 has already passed phase III and been APPROVED in Europe for PTW's. AP101 is a treatment applied to the skin, so is NOT a drug that is ingested by the patient. I have no idea whether MTFB's product is a skin treatment, or a drug that is ingested by the patient, but I suspect the latter.

The AMYT chart doesn't look good.

[papillon] 17/2/2019 17:04

I totally agree, Solomon

[solomon] 17/2/2019 14:33

I hope he's okay. He sounded like an exceptionally decent guy.

[papillon] 17/2/2019 12:39

O/T greendragon777 hasn't posted on AMYT since the 4th January. In fact he hasn't posted on any ADVFN bb since 4th January.

I know he was keen on cryptocurrencies. His favourite cryptocurrency, IOTA, gets a special mention in the ongoing Quadriga scandal as this BBC article shows:

[volsung] 14/2/2019 12:12

Bought some MTFB. Might be a bit of overreaction there. They will go back and talk to the FDA

[papillon] 14/2/2019 11:05

One biopharma has "tanked" today. MTFB is down an absolutely staggering 86% today!!!!

[papillon] 13/2/2019 22:42

radar
Posts: 2,798
Opinion:
No Opinion
Price:
15.80
RE: Big seller out there?
Mon 17:30
Looks like its going to tank soon.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Has it tanked yet, Einstein? radar? Plonker!

[papillon] 12/2/2019 14:44

You could be correct, bioking. I certainly hope so. It's why I have been holding AMYT ever since it listed. It's my largest holding and I have added over the years. I'm breaking even at the current 16p share price

[bioking] 12/2/2019 14:15

all i can say is strong buy aggressive i think this one has even higher potential than fum .

[papillon] 12/2/2019 13:33

Well, chica1, the recent RNS states



"Amryt will begin the recruitment process for the additional patients required and now expects a readout of the top line data from the EASE study in H2 2019."

So the company states the AP101 trial results will be available in H2 2019. Whether that proves to be correct, or drags into 2020, only time will tell. 1/6/2019 to 31/12/2019 is a very wide spread. Hopefully the company is finally being cautious on timelines and the results will be available in Q3 2019 rather than Q4 2019, but who knows. You pays your money and takes your choice.

[chica1] 12/2/2019 12:12

Just new here..Hasn't AP101 trial results been pushed out to early 2020 as they are adding more patients?

[bioking] 12/2/2019 07:55

nobody is ramping this stock and its still unknown to most investors and thats a big reason why volume is low. i just mentioned this stock on fum board but thats not what i call ramping . stock is dirt cheap and soon it will run higher ahead of the phase 3 readout and a potential buyout is not out of question .

[papillon] 11/2/2019 15:27

Well the share price is not yet reaping the benefits of the ramping efforts of bioking & ih_116147. LOL.

The AMYT share price desperately needs good news and fast.

[papillon] 08/2/2019 13:28

ih_116147, mdalos, is just a desperate ramper. We've had them posting before on this bb and their ramping is just ignored. What he posts in 4242 is old news, even if it's in a new article. I notice he hasn't posted a link to this new article, assuming it exists! I wonder if he's copying what has just been posted on the new iii AMYT bb that bioking was going on about recently?

One thing is guaranteed and that's ih_116147 ramping will have zero effect on the AMYT share price It needs good news, or the anticipation of good news, for the AMYT share price to rise and not desperate ramping.